{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:07:04Z","timestamp":1773965224462,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jgar.2023.09.004","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:36:24Z","timestamp":1694640984000},"page":"143-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015\u20132021"],"prefix":"10.1016","volume":"35","author":[{"given":"Luis C.","family":"Torres-Castillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecil","family":"Fandi\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Paz","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge A.","family":"Ramos-Castaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda L.","family":"Rioseco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrystal","family":"Juliet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2023.09.004_bib0001","series-title":"Estrategia mundial de la OMS para contener la resistencia a los antimicrobianos","first-page":"10","year":"2001"},{"key":"10.1016\/j.jgar.2023.09.004_bib0002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2023.09.004_bib0003","unstructured":"O'Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. 2014. Review on Antimicrobial Resistance. London: HM Government."},{"key":"10.1016\/j.jgar.2023.09.004_bib0004","unstructured":"Pew Charitable Trusts. Antibiotics currently in clinical development. Technical report; 2017."},{"key":"10.1016\/j.jgar.2023.09.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106045","article-title":"In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015\u20132017","volume":"56","author":"Stone","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2023.09.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.05.007","article-title":"Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012\u20132016","volume":"96","author":"Stone","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2023.09.004_bib0007","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1093\/cid\/ciaa084","article-title":"Impact of difficult-to-treat resistance in Gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data","volume":"71","author":"Huh","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.09.004_bib0008","doi-asserted-by":"crossref","DOI":"10.1186\/s12941-017-0191-3","article-title":"Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae","volume":"16","author":"Xu","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2023.09.004_bib0009","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jinf.2018.02.007","article-title":"Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: systematic review and meta-analysis","volume":"76","author":"Ramos-Casta\u00f1eda","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2023.09.004_bib0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4067\/S0716-10182017000100001","article-title":"Factores asociados a nefrotoxicidad por polimixina B en un hospital universitario de Neiva, Colombia. 2011\u20132015","volume":"34","author":"Osorio","year":"2017","journal-title":"Revista chilena de infectolog\u00eda"},{"key":"10.1016\/j.jgar.2023.09.004_bib0011","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/cc3995","article-title":"Toxicity of polymyxins: a systematic review of the evidence from old and recent studies","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.jgar.2023.09.004_bib0012","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.09.004_bib0013","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/jac\/dkv170","article-title":"Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens","volume":"70","author":"Nicolau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.09.004_bib0014","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2147\/IDR.S209264","article-title":"Optimal management of complicated infections in the pediatric patient: the role and utility of ceftazidime\/avibactam","volume":"13","author":"Bassetti","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2023.09.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106439","article-title":"Activity of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales (CRE) isolates from US hospitals","author":"Castanheira","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2023.09.004_bib0016","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/antibiotics9020062","article-title":"In vitro susceptibility to ceftazidime\/avibactam and comparators in clinical isolates of enterobacterales from five Latin American countries","volume":"9","author":"Appel","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2023.09.004_bib0017","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jgar.2022.09.012","article-title":"Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019","volume":"31","author":"Kempf","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2023.09.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2022.102369","article-title":"In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014\u20132018","volume":"26","author":"Lemos-Luengas","year":"2022","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jgar.2023.09.004_bib0019","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgar.2022.02.018","article-title":"In vitro activity of ceftazidime\/avibactam against Gram-negative strains in Colombia 2014\u20132018","volume":"29","author":"Lemos-Luengas","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2023.09.004_bib0020","unstructured":"Instituto de Salud P\u00fablica, Ministerio de Salud. Ficha Productos Registrados. http:\/\/registrosanitario.ispch.gob.cl\/Ficha.aspx?RegistroISP=F-24968\/19 [accessed 3 Feb 2023]."},{"key":"10.1016\/j.jgar.2023.09.004_bib0021","unstructured":"Pfizer. ATLAS (Antimicrobial Testing Leadership and Surveillance). https:\/\/atlas-surveillance.com\/\/#\/login."},{"key":"10.1016\/j.jgar.2023.09.004_bib0022","series-title":"ATLAS: Fully searchable Global Antibiotic Resistance Database to Fight AMR Testing","author":"Scientific","year":"2019"},{"key":"10.1016\/j.jgar.2023.09.004_bib0023","unstructured":"Clinical Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standards. Wayne, PA; 2018. CLSI document M07-A11."},{"key":"10.1016\/j.jgar.2023.09.004_bib0024","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA; 2019. CLSI Document M100S."},{"key":"10.1016\/j.jgar.2023.09.004_bib0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jgar.2021.08.010","article-title":"In vitro activity of ceftazidime\/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018","volume":"27","author":"Kiratisin","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2023.09.004_bib0026","first-page":"1","article-title":"The ERACE-PA global surveillance program: ceftolozane\/tazobactam and ceftazidime\/avibactam in vitro activity against a global collection of carbapenem-resistant Pseudomonas aeruginosa","author":"Gill","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2023.09.004_bib0027","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/mdr.2022.0175","article-title":"Susceptibility of multidrug-resistant Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from Germany to ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam","volume":"29","author":"Kresken","year":"2023","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2023.09.004_bib0028","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.09.004_bib0029","article-title":"Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis","volume":"9","author":"Fiore","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2023.09.004_bib0030","article-title":"Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant Gram-negative bacteria other than carbapenem-resistant Enterobacterales","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2023.09.004_bib0031","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children\u2265 3 months to< 18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2023.09.004_bib0032","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and efficacy of ceftazidime\u2013avibactam in the treatment of children \u22653 months to <18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2023.09.004_bib0033","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.09.004_bib0034","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523001480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523001480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:00:44Z","timestamp":1761991244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716523001480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":34,"alternative-id":["S2213716523001480"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2023.09.004","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015\u20132021","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2023.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}